IDEAS home Printed from https://ideas.repec.org/h/spr/lnichp/978-3-031-65782-5_10.html
   My bibliography  Save this book chapter

New Medicines Design, Development and Commercialization in the Era of AI

In: Leading and Managing in the Digital Era

Author

Listed:
  • Magnus Nydén

    (AstraZeneca)

  • Dafni Bika

    (AstraZeneca)

Abstract

The escalating demand for innovative therapies and increasing chronic disease incidence pose significant challenges to the pharmaceutical industry. Regulatory bodies are prioritizing more cost-effective, sustainable solutions with greater transparency. In response, AstraZeneca is evolving its strategies to prioritize speed, sustainability, and cost-effectiveness, while maintaining quality and patient safety. We are leveraging advancements in data-centric science, digital twin technology, and AI, including generative AI, to expedite clinical trials and streamline drug development. Our digital transformation is rooted in a profound understanding of drug substance and product, clinical supply chain planning, and manufacturing. This shift is facilitated by data, novel business processes, and human skills. We are entering a new era of digital innovations, where our pharmaceutical development expertise is strengthened by tools like generative AI and deep understanding of various scientific disciplines. This paper provides an overview of our activities and methodology for digital innovations relevant to pharmaceutical technology and development. It delves into the Drug Development Holistic Digital Twin concept, aimed at transforming our work methods, productivity, and innovation, and concludes with an update on progress and future plans.

Suggested Citation

  • Magnus Nydén & Dafni Bika, 2024. "New Medicines Design, Development and Commercialization in the Era of AI," Lecture Notes in Information Systems and Organization, in: Gregory Prastacos & Nancy Pouloudi (ed.), Leading and Managing in the Digital Era, pages 137-155, Springer.
    • Handle: RePEc:spr:lnichp:978-3-031-65782-5_10
    DOI: 10.1007/978-3-031-65782-5_10
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a search for a similarly titled item that would be available.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:lnichp:978-3-031-65782-5_10. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.